SCHEDULE: Commodore Capital Discloses 7.7% Stake in Enliven

Commodore Capital LP and its principals have reported a 7.7% beneficial ownership stake in Enliven Therapeutics, Inc. as of March 31, 2026.

Summary

• Commodore Capital LP, Commodore Capital Master LP, and managing partners Robert Egen Atkinson and Michael Kramarz filed a Schedule 13G reporting beneficial ownership of 4,800,940 shares of Enliven Therapeutics, Inc.
• The reported stake represents 7.7% of the company's outstanding common stock.
• The holdings consist of 3,275,000 shares of common stock and 1,525,940 shares issuable upon the exercise of pre-funded warrants.
• The filing confirms the investment is held for passive purposes and not to influence or change control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it reflects stable institutional support without indicating any immediate corporate distress or strategic shift.

Positives

• Institutional backing from a specialized investment firm indicates confidence in the company's long-term prospects.
• The investment includes a significant portion of pre-funded warrants, suggesting a long-term commitment to the equity.

Negatives

• The filing notes a 9.99% beneficial ownership limitation on the pre-funded warrants, which restricts immediate conversion flexibility.

Risks

• Market volatility affecting the valuation of the 7.7% stake.
• Potential dilution if the company issues additional shares in future capital raises.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, as it is a disclosure of beneficial ownership.

Management Comments

• The reporting persons certify that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by specialized healthcare investment firms like Commodore Capital are common in the biotech sector, often signaling institutional validation of a company's clinical pipeline or strategic direction.

Comparison to Industry Standards

• The 7.7% stake is consistent with typical institutional position sizing for mid-cap biotechnology firms.
• The use of pre-funded warrants is a standard mechanism in biotech financing to provide capital while managing regulatory ownership thresholds.

Stakeholder Impact

• Shareholders may view the disclosure of a significant institutional position as a sign of stability.
• The 9.99% ownership cap on warrants provides a safeguard against sudden shifts in control.

Next Steps

• Future amendments to the Schedule 13G will be filed if there are material changes to the percentage of ownership.

Key Dates

Keywords

Enliven Therapeutics, Commodore Capital, Schedule 13G, Biotech, Institutional Ownership, Equity Investment